In this article
New Qβ Virus-Like Particle Vaccine Research
Scientists at Michigan State University are designing a virus-like particle called Qβ, which will generate an anti-cancer immune response in the body and may be used as a new vaccine for cancer treatment. The US $ 2.4 million project funded by the National Institute will support the development of vaccines to protect animals from cancer cells that are currently incurable, and may well be a vaccine for spontaneous cancer in humans.
The team will combine Qβ particles with tumor-associated carbohydrate antigens (TACAs), and they believe these antigens will produce complete anti-tumor cell immunity, reduce tumor growth and prevent tumor development. In addition, the researchers will use the crystal structure of Qβ to develop mutations that reduce toxic antibodies and promote the desired cells, which can also kill cancer cells. This is the first such trial using a TACA vaccine model.
Canine Osteosarcoma Trials and Future Applications
This vaccine will be used first to treat canine cancer and will focus on osteosarcoma, which is a refractory dog and human bone tumor.
Vaccines can reduce growth and protect patients from tumor progression and further progress. If we can further understand the relationship between the structural characteristics of Qβ-TACA and anti-tumor immunity, it can have a great effect on the design of cancer vaccines. This research also strengthens the important role of veterinary medicine in cancer research.
Yuzbasiyan-Gurkan said: “Spontaneous cancer in dogs and cats provides a real test for . This is just one example of the many ways in which veterinary and human medical research can benefit each other.”
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Susan Hau
Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy. Hau's expertise lies in cancer cell biolo…
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.